PECULIARITIES OF DORNASE ALFA AND KINESITHERAPY USE IN CHILDREN WITH CYSTIC FIBROSIS

Abstract

The article is dedicated to modern treatment of mucoviscidosis. The article covers issues of pathogenesis and emphasizes importance of mucociliary clearance and anatomic-physiological peculiarities of respiratory tract’s structure in childhood in the development of the disease. The article shows that efficient treatment of this disease requires an early beginning of pathogenetic treatment in combination with kinesitherapy. The article shows that the currently used drug – dornase alfa – has 3 key clinical effects – mucolytic, anti-inflammatory and antibacterial. Complex action of dornase alfa should be remembered; the treatment should be continued to prevent development of infectious complications typical for mucoviscidosis. The article also lists general rules of conducting inhalations and using dornase alfa in combination with kinesitherapy.

Keywords

• mucoviscidosis
• pathogenesis
• treatment
• mucociliary clearance
• enzymatic mucolytic
• kinesitherapy
• children